| [1] |
Wu J, Li J, Zhu G, et al. Clinical features of maintenance hemodialysis patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China [J]. Clin J Am Soc Nephrol, 2020, 15(8): 1139-1145.
|
| [2] |
Mehta P, Mcauley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression [J]. Lancet, 2020, 395(10229): 1033-1034.
|
| [3] |
Harm S, Schildböck C, Hartmann J. Cytokine removal in extracorporeal blood purification: an in vitro study [J]. Blood Purif, 2020, 49(1-2): 33-43.
|
| [4] |
Allegra A, Di Gioacchino M, Tonacci A, et al. Immunopathology of SARS-CoV-2 infection: immune cells and mediators, prognostic factors, and immune-therapeutic implications [J]. Int J Mol Sci, 2020, 21(13): 4782.
|
| [5] |
Ruiz-Rodríguez JC, Molnar Z, Deliargyris EN, et al. The use of CytoSorb therapy in critically ill COVID-19 patients: review of the rationale and current clinical experiences [J]. Crit Care Res Pract, 2021, 2021: 7769516.
|
| [6] |
Malard B, Lambert C, Kellum JA. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices [J]. Intensive Care Med Exp, 2018, 6(1): 12.
|
| [7] |
Rosalia RA, Ugurov P, Neziri D, et al. Extracorporeal blood purification in moderate and severe COVID-19 patients: a prospective cohort study [J]. Blood Purif, 2022, 51(3): 233-242.
|
| [8] |
Ronco C, Tetta C, Mariano F, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis [J]. Artif Organs, 2003, 27(9): 792-801.
|
| [9] |
Ugurov P, Popevski D, Gramosli T, et al. Early initiation of extracorporeal blood purification using the AN69ST (oXiris®) hemofilter as a treatment modality for COVID-19 patients: a single-centre case series [J]. Braz J Cardiovasc Surg, 2022, 37(1): 35-47.
|
| [10] |
Gubernatorova EO, Gorshkova EA, Polinova AI, et al. IL-6: relevance for immunopathology of SARS-CoV-2 [J]. Cytokine Growth Factor Rev, 2020, 53: 13-24.
|